A prospective study on associations between superoxide dismutase gene polymorphisms and antituberculosis drug‐induced liver injury in a Chinese Han population

2019 ◽  
Vol 21 (10) ◽  
Author(s):  
Tao Wu ◽  
Hao Bai ◽  
Zhenzhen Zhao ◽  
Minjin Wang ◽  
Xuejiao Hu ◽  
...  
Keyword(s):  
Superoxide Dismutase ◽  
Liver Injury ◽  
Gene Polymorphisms ◽  
Antituberculosis Drug ◽  
Chinese Han ◽  
Drug Induced ◽  
Han Population ◽  
Drug Induced Liver Injury ◽  
Superoxide Dismutase Gene ◽  
A Prospective Study

scholarly journals Relationship between CYP2E1 Gene Polymorphism and Anti-tuberculosis Drug-induced Liver Injury

2018 ◽  
Vol 1 (4) ◽  
pp. 105
Author(s):  
Donglin Zhu ◽  
Yun Xi ◽  
Jieming Dong ◽  
Fanhua Huang ◽  
Changzhi Xu ◽  
...  
Keyword(s):  
Liver Injury ◽  
Gene Polymorphism ◽  
Liver Damage ◽  
Gene Polymorphisms ◽  
Control Group ◽  
Case Group ◽  
Chinese Han ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Cyp2e1 Gene

 Objective: To investigate the relationship between cytochrome P450 E1 (CYP2E1) gene polymorphisms and susceptibility to anti-tuberculosis drug-induced liver damage (ATDLI) in tuberculosis patients in the Chinese Han nationality. Methods: A retrospective analysis was performed on 360 patients with tuberculosis who had liver damage after tuberculosis treatment (case group) and 360 patients with tuberculosis who did not develop liver injury after treatment (control group). MassARRAY were used to detect CYP2E1 gene polymorphisms. Results: In a total of 8 tagged SNP loci selected, the rs8192773 locus failed to pass the test, and therefore, it is not included in subsequent analysis. At the remaining seven SNP sites, the difference in alleles was not statistically significant between the case group and the control group, suggesting that these sites may not be related to liver damage caused by anti-tuberculosis drugs. Three monomer domains were found in the seven tags SNP loci mentioned above. However, it was found that these haplotypes are not closely related to anti-tuberculosis drug-induced liver damage. Conclusion: The CYP2E1 gene polymorphism in the Chinese Han nationality is not related to the occurrence of anti-tuberculosis drug-induced liver injury.

scholarly journals CYP2E1, GSTM1, and GSTT1 genetic polymorphisms and their associations with susceptibility to antituberculosis drug-induced liver injury in Thai tuberculosis patients

Heliyon ◽  
2021 ◽  
Vol 7 (4) ◽  
pp. e06852
Author(s):  
Noppadol Chanhom ◽  
Sukanya Wattanapokayakit ◽  
Nusara Satproedprai ◽  
Supharat Suvichapanich ◽  
Surakameth Mahasirimongkol ◽  
...  
Keyword(s):  
Liver Injury ◽  
Genetic Polymorphisms ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Tuberculosis Patients ◽  
Drug Induced Liver Injury

scholarly journals Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury

2015 ◽  
Vol 105 (5) ◽  
pp. 393 ◽  
Author(s):  
S Naidoo ◽  
D Evans ◽  
E Jong ◽  
K Mellet ◽  
R Berhanu
Keyword(s):  
Liver Injury ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury

scholarly journals Genetic Risk Factors in Drug‐Induced Liver Injury Due to Isoniazid‐Containing Antituberculosis Drug Regimens

2020 ◽  
Author(s):  
Paola Nicoletti ◽  
Harshad Devarbhavi ◽  
Ashish Goel ◽  
Radha Venkatesan ◽  
Chundamannil E. Eapen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Injury ◽  
Genetic Risk ◽  
Genetic Risk Factors ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Drug Regimens

scholarly journals Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Lina Tao ◽  
Xiaoyu Qu ◽  
Yue Zhang ◽  
Yanqing Song ◽  
Si-xi Zhang
Keyword(s):  
Liver Injury ◽  
Liver Function ◽  
Randomized Controlled Trials ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Prophylactic Therapy ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Randomized Controlled

Background. Prophylactic therapy with silymarin to prevent the development of antituberculosis drug-induced liver injury (anti-TB DILI) has been under debate. We aimed to evaluate the effect of silymarin in the prevention of anti-TB DILI. Methods. We searched MEDLINE, PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) up to 30th November 2018. Randomized controlled trials (RCTs) that compared silymarin and placebo to prevent anti-TB DILI were included. All statistical analyses were conducted using STATA 12.0 software. Standardized mean difference (SMD) and risk ratio (RR) with 95% confidence intervals (CIs) were used to evaluate the effect of silymarin. The quality of included studies was assessed according to Cochrane handbook. Funnel plots and Egger’s tests were carried out to evaluate publication bias. Sensitivity analysis was conducted to assess the influence of each study. Results. A total of 1198 patients from five RCTs (585 with silymarin and 613 with placebo groups) were included. Overall, silymarin significantly reduced the occurrence of anti-TB DILI at week 4 [RR: 0.33, 95% CI (0.15, 0.75)]. In addition, silymarin exerted protective effect on liver function in patients undergoing anti-TB drugs [SMD = − 0.15, 95% CI (−0.24, −0.07), P < 0.001 (ALT); SMD =−0.14, 95% CI (−0.23, −0.06), P = 0.001(AST); SMD =−0.12, 95% CI (−0.20, −0.03), P = 0.008 (ALP)]. Silymarin led to similar AEs in placebo groups [OR: 1.09, 95% CI (0.86, 1.39), P = 0.47]. Conclusion. Prophylactic therapy of silymarin is contributed to a noticeably reduced risk of development of anti-TB DILI four weeks after the initiation. In addition, silymarin significantly improved the liver function in patients who are receiving anti-TB drugs.

Sign in / Sign up

Export Citation Format

Share Document